Atopic dermatitis (AD) is an immune disorder, characterized by chronic skin inflammation or relapsing, whose prevalence is increasing worldwide. Its exact etiology remains unknown. The hypothesis that an appropriate early stimulation of the intestinal flora contributes to the establishment of the immune system balance has led to the use of probiotics in the prevention and treatment of AD in several clinical and experimental studies. Therefore, the objectives of this study will evaluate the clinical efficacy of the mixture of probiotics (Lactobacillus and Bifidobacterium) in children with AD through the SCORAD (scoring atopic dermatitis) and to evaluate the effects of this medication in the following laboratory parameters: skin prick test, total serum immunoglobulin E (IgE), inflammation composite (interferon gamma \[ɣ - IFN\], interleukins \[IL1-β, IL-4, IL-6, IL-8\] and tumor necrosis factor alpha) and immune tolerance composite (IL-10, IL-17 and transforming growth factor beta \[TGF - β\]).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
Hospital das Clínicas FMRP-USP
Ribeirão Preto, São Paulo, Brazil
SCORAD
Change from baseline in SCORAD every 3 months for 1 year
Time frame: 1 year
Skin prick test (immediate awareness)
Time frame: 1 year
Inflammation composite
ɣ - IFN, IL-1β, IL -4 , IL -6, IL-8 and tumor necrosis factor
Time frame: 1 year
Immune tolerance composite
IL-10, TGF - β and IL -17
Time frame: 1 year
Total serum IgE
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.